Efanesoctocog Alfa for the Management of a Life-Threatening Intracranial Haemorrhage in Mild Haemophilia A: A Case Report.
- 1Hematology and Hemotherapy, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, ESP.
- 2Hematology and Hemotherapy, Hospital Universitario Álvaro Cunqueiro, Instituto de Investigación Sanitaria Galicia Sur (IISGS), Estructura Organizativa de Xestión Integrada (EOXI) de Vigo, Vigo, ESP.
Abstract
Mild haemophilia A (HA; baseline factor VIII (FVIII) 5-40 IU/dL) is usually free of spontaneous bleeding, but high-energy trauma or major surgery can precipitate life-threatening haemorrhage requiring prolonged haemostatic coverage. These patients are typically treated on demand, are rarely trained in self-infusion, and lack an established treatment model. Efanesoctocog alfa, a first-in-class FVIII replacement therapy with a high sustained activity (HSA), has been studied almost exclusively in severe HA. We report a 33-year-old man with mild HA (baseline FVIII 22 IU/dL) who sustained a severe traumatic left temporal epidural haematoma with associated skull-base and pelvic fractures. After an initial standard FVIII bolus, he was managed with efanesoctocog alfa using a progressively spaced regimen, with FVIII monitored by chromogenic assay corrected per the manufacturer's recommendation. Complete radiological resolution occurred by week 8 without rebleeding; no inhibitor developed. The bleed was controlled with only seven infusions in the first 14 days and without central venous access, tapering to conventional weekly dosing. We discuss why the pharmacokinetic profile of efanesoctocog alfa is particularly advantageous in the mild phenotype and how the same properties extend to major surgery, together with a cautious appraisal of its cost profile, which is strongly dependent on the healthcare system.
Related
- Classic case report: concomitant pulsed field ablation, cavotricuspid isthmus ablation and percutaneous left atrial appendage occlusion in a patient with prior intracranial haemorrhage.
- Intracranial Haemorrhage and Haemorrhagic Stroke in Patients with Atrial Fibrillation on Edoxaban in ETNA-AF-Europe
- Refining Clinical Management Advice From Radiology for Intracerebral Haemorrhage: A Two-Cycle Clinical Audit With Intervening Service Improvement.
- Blood pressure management in acute intracerebral haemorrhage: a Time–Trajectory–Phenotype framework
- Delayed rupture of vaginal wall haematoma causing secondary postpartum haemorrhage—successful management with bilateral uterine artery embolisation: a case report
BibTeX
@article{seoane2026efanesoctocog,
title = {{Efanesoctocog Alfa for the Management of a Life-Threatening Intracranial Haemorrhage in Mild Haemophilia A: A Case Report.}},
author = {Laura C Seoane and Paula S Fuentes and Patricia S Diaz and Manuel R Lopez},
journal = {Cureus},
year = {2026},
month = oct,
doi = {10.7759/cureus.118716},
url = {https://europepmc.org/article/MED/42953672},
note = {CC BY},
}
RIS
TY - JOUR
TI - Efanesoctocog Alfa for the Management of a Life-Threatening Intracranial Haemorrhage in Mild Haemophilia A: A Case Report.
AU - Laura C Seoane
AU - Paula S Fuentes
AU - Patricia S Diaz
AU - Manuel R Lopez
PY - 2026
DA - 2026/10/28
JO - Cureus
DO - 10.7759/cureus.118716
UR - https://europepmc.org/article/MED/42953672
AB - Mild haemophilia A (HA; baseline factor VIII (FVIII) 5-40 IU/dL) is usually free of spontaneous bleeding, but high-energy trauma or major surgery can precipitate life-threatening haemorrhage requiring prolonged haemostatic coverage. These patients are typically treated on demand, are rarely trained in self-infusion, and lack an established treatment model. Efanesoctocog alfa, a first-in-class FVIII replacement therapy with a high sustained activity (HSA), has been studied almost exclusively in severe HA. We report a 33-year-old man with mild HA (baseline FVIII 22 IU/dL) who sustained a severe traumatic left temporal epidural haematoma with associated skull-base and pelvic fractures. After an initial standard FVIII bolus, he was managed with efanesoctocog alfa using a progressively spaced regimen, with FVIII monitored by chromogenic assay corrected per the manufacturer's recommendation. Complete radiological resolution occurred by week 8 without rebleeding; no inhibitor developed. The bleed was controlled with only seven infusions in the first 14 days and without central venous access, tapering to conventional weekly dosing. We discuss why the pharmacokinetic profile of efanesoctocog alfa is particularly advantageous in the mild phenotype and how the same properties extend to major surgery, together with a cautious appraisal of its cost profile, which is strongly dependent on the healthcare system.
SN - 2168-8184
ER -